|
1）骨粗鬆症の予防と治療ガイドライン作成委員会．第IV章続発性骨粗鬆症．B．疾患関連骨粗鬆症．ｂ生活習慣病関連骨粗鬆症．（1）糖尿病．In: 折茂 肇，他編．骨粗鬆症の予防と治療のガイドライン2015年版．東京: ライフサイエンス出版; 2015. p.130-1
|
|
|
|
|
2）日本骨粗鬆症学会，生活習慣病における骨折リスク評価委員会．第2章 骨折リスクに関連する生活習慣病 1 糖尿病．In: 杉本利嗣，他編．生活習慣病骨折リスクに関する診療ガイド．東京: ライフサイエンス出版; 2011. p.25-9
|
|
|
|
|
|
3）McNair P. Bone mineral metabolism in hyman type 1 (insulin dependent) diabetes mellitus. Dan Med Bull. 1988; 35: 109-21
|
|
|
|
|
4）Schwartz AV. Diabetes mellitus: does it affect bone? Calcif Tissue Int. 2003; 73: 515-9
|
|
|
|
|
5）Jehle PM, Jehle DR, Mohan S, et al. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetesmellitus patients. J Endocrinol. 1988; 159: 297-306
|
|
|
|
|
|
6）Reid IR, Evans MC, Cooper GJ, et al. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 1993; 265: E655-9
|
|
|
|
|
|
7）Weaver VM, Welsh JE. Effect of in vivo and in vitro insulin on renal 25(OH)D3 hydroxylation in insulin dependent diabetic rats. Diabetes Res. 1994; 25: 107-19
|
|
|
|
|
|
8）Al-Qadreh A, Voskaki I, Kassiou C, et al. Treatment of osteopenia in children with insulin-dependent diabetes mellitus: the effect of 1 alpha-hydroxyvitamin D3. Eur J Pediatr. 1996; 155: 15-7
|
|
|
|
|
|
9）Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010; 31: 266-300
|
|
|
|
|
|
10）Iyer S, Ambrogini E, Bartell SM, et al. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest. 2013; 123: 3409-19
|
|
|
|
|
|
11）Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int. 2012; 91: 286-96
|
|
|
|
|
|
12）Saito M, Marumo K. Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int. 2015; 97: 242-61
|
|
|
|
|
|
13）Farlay D, Armas L, Gineyts E, et al. Non-enzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2015 Aug 1. doi: 10.1002/jbmr.2607
|
|
|
|
|
|
14）Tanaka K, Kanazawa I, Sugimoto T. Reduction in endogenous insulin secretion is a risk factor of sarcopenia in men with type 2 diabetes mellitus. Calcif Tissue Int. 2015; 97: 385-90
|
|
|
|
|
|
15）Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012; 481: 314-20
|
|
|
|
|
|
16）Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2diabetes-a meta-analysis. Osteoporos Int. 2007; 18: 427-44
|
|
|
|
|
|
17）Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 1013-9
|
|
|
|
|
|
18）Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009; 24: 702-9
|
|
|
|
|
|
19）Westberg-Rasmussen S, Starup-Linde J, Gregersen S, et al. Predictors of mortality subsequent to a fracture in diabetes mellitus patients. Front Endocrinol (Lausanne). 2015 Apr 1; 6: 46. doi: 10.3389/fendo.2015.00046
|
|
|
|
|
|
20）Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013; 28: 313-24
|
|
|
|
|
|
21）Bala Y, Zebaze R, Ghasem-Zadeh A,et al. Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res. 2014; 29: 1356-62
|
|
|
|
|
|
22）Hans D, Goertzen AL, Krieg MA, et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011; 26: 2762-9
|
|
|
|
|
|
23）Kim JH, Choi HJ, Ku EJ, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015; 100: 475-82
|
|
|
|
|
|
24）Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014; 29: 787-95
|
|
|
|
|
|
25）Moester MJ, Papapoulos SE, Lowik CW, et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87: 99-107
|
|
|
|
|
|
26）Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 1737-44
|
|
|
|
|
|
27）Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013; 98: 4030-7
|
|
|
|
|
|
28）Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015; 30: 216-24
|
|
|
|
|
|
29）McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370: 412-20
|
|
|
|
|
|
30）McDonough AK, Rosenthal RS, Cao X, et al. The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab. 2008; 4: 507-13
|
|
|
|
|
|
31）Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180: 32-9
|
|
|
|
|
|
32）Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010; 95: 592-600
|
|
|
|
|
|
33）Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012; 14: 990-9
|
|
|
|
|
|
34）Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 ; 16: 159-69
|
|
|
|
|
|
35）Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34: 2474-6
|
|
|
|
|
|
36）Driessen JH, van Onzenoort HA, Starup-Linde J, et al. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs. Pharmacoepidemiol Drug Saf. 2015; 24: 1017-25
|
|
|
|
|
|
37）Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305: 2184-92
|
|
|
|
|